
ATTO Stock Forecast & Price Target
ATTO Analyst Ratings
Bulls say
Attovia Therapeutics is a biotechnology company focused on developing innovative biologics for immune-mediated diseases, with a promising product pipeline including ATTO-1310, ATTO-2306, and ATTO-1091. These drug candidates utilize the company's ATTOBODY platform, which has shown potential for optimized efficacy and convenience profiles. With a strong R&D engine and a highly validated approach, Attovia Therapeutics has the potential to capture a significant market share in the treatment of immune-related diseases.
Bears say
Attovia Therapeutics is a clinical stage biotechnology company developing biologics for immune-mediated diseases. Their comprehensive pipeline includes ATTO-1310, an antibody targeting IL-31, which has demonstrated favorable improvements in itch for chronic pruritus and atopic dermatitis, and is expected to enter Phase II trials in 2027. While their YTE half-life extension technology has been validated, the increasingly competitive landscape, potential for safety signals to emerge, and other risks pose uncertainty for their ability to finance ongoing research, garner regulatory approval, and successfully commercialize their products.
This aggregate rating is based on analysts' research of Attovia Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ATTO Analyst Forecast & Price Prediction
Start investing in ATTO
Order type
Buy in
Order amount
Est. shares
0 shares